Matthew M. Riggs, Ph.D.

Chief Science Officer

Matt offers over 16 years of industry experience including the application of modeling and simulation for clinical pharmacology and later phase drug development decisions. Matt’s interests include the development and application of mechanistic exposure-response and systems pharmacology models to quantitatively integrate physiology, pharmacology, senescence and disease understandings; this to guide translational and clinical research toward improved preventative and interventional therapeutics.

Recent publications by this scientist

A Population Pharmacokinetic-Pharmacodynamic Model Evaluating Efficacy of Nalbuphine Extended-Release in Patients with Prurigo Nodularis

January 27, 2023

Rena Eudy-Byrne, Matthew Riggs, Amale Hawi, Thomas Sciascia, Shashank Rohatagi. Br J Clin Pharmacol. 2023.  doi:10.1111/bcp.15663

View More

Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda

November 14, 2022

Katherine Kay, Justin Goodwin, Hanna Ehrlich, Joyce Ou, Tracey Freeman, Kaicheng Wang, Fangyong Li, Martina Wade, Jonathan French, Liusheng Huang, Francesca Aweeka, Norah Mwebaza, Richard Kajubi, Matthew Riggs, Ana Ruiz-Garcia, Sunil Parikh. Clin Pharmacol Ther. Published online October 19, 2022. doi:10.1002/cpt.2768

Download PDF

View More

Association of lumefantrine pharmacokinetics and resistance selection following artemether-lumefantrine treatment in children with and without HIV in Uganda

November 10, 2022

Katherine Kay, Justin Goodwin, Hanna Ehrlich, Joyce Ou, Tracy Freeman, Kaicheng Wang, Fangyong Li, Martina Wade, Jonathan French, Liusheng Huang, Francesca T. Aweeka, Norah Mwebaza, Richard Kajubi, Matthew Riggs, Ana Ruiz-Garcia, Sunil Parikh. Poster presented at American Society of Tropical Medicine and Hygiene (ASTMH). October 30 – November 3, 2022. Poster #1434.

Download PDF